RxDoctor Payments Data

Sarah Wolf, DO

Internal Medicine · Harbor Springs, MINPI 1952727653

Payments from drug & device makers

$834in general payments, 2019–2025

Across 54 payments — averaging $15.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$286
  • Novo Nordisk$135
  • AbbVie$102
  • GSK$75
  • Astellas Pharma US Inc$54
  • AstraZeneca$54
  • plus $126 from 7 others

What the payments were for

  • Food & beverage$834100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$834 in reported general payments places this provider in the 70th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$70,669
Medicare patients
191
Services billed
920

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide81$118,194
JardianceEmpagliflozin72$77,540
OzempicSemaglutide34$61,525
Dupixent SyringeDupilumab14$60,921
EliquisApixaban46$60,003
TrulicityDulaglutide25$49,616
FarxigaDapagliflozin Propanediol29$35,010
JanuviaSitagliptin Phosphate28$34,343
XareltoRivaroxaban21$33,912
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$29,257
Repatha SureclickEvolocumab18$15,259
JanumetSitagliptin Phos/Metformin Hcl18$15,202
Atorvastatin Calcium478$8,469
Rosuvastatin Calcium388$8,343
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate24$5,269

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$135$61,52534 claims
PfizerEliquis$13$60,00346 claims
MerckJanuvia, Janumet$12$49,54546 claims
AstraZenecaFarxiga$54$35,01029 claims
Johnson & JohnsonXarelto$6$33,91221 claims
GSKTrelegy Ellipta$75$29,25727 claims
AbbVieSynthroid$102$4,01846 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Harbor Springs

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →